Saniona acquires headquarters to secure long-term stability
19 juni, 08:00
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the acquisition of its current headquarters in Glostrup, Denmark. This move secures long-term operational stability, supports the company’s development plans, and provides greater control over infrastructure and cost structure as the company advances treatments for neurological and psychiatric diseases.
“Securing our headquarters not only strengthens our operational base but also reflects our confidence in Saniona’s future. It allows us to continue progressing our clinical programs without disruption and with greater financial flexibility. The premises are located in an area undergoing transformation into highly sought-after residential district, which positions the deal to be financially advantageous over time,” said Thomas Feldthus, CEO of Saniona.
Saniona will fund the acquisition of DKK 49 million from existing cash reserves but is also evaluating alternative financing options, such as a potential sale and leaseback arrangement, to optimize capital allocation and maintain strategic agility.
For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona’s partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Attachments
Saniona acquires headquarters to secure long-term stability
Ämnen i artikeln
Saniona acquires headquarters to secure long-term stability
19 juni, 08:00
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the acquisition of its current headquarters in Glostrup, Denmark. This move secures long-term operational stability, supports the company’s development plans, and provides greater control over infrastructure and cost structure as the company advances treatments for neurological and psychiatric diseases.
“Securing our headquarters not only strengthens our operational base but also reflects our confidence in Saniona’s future. It allows us to continue progressing our clinical programs without disruption and with greater financial flexibility. The premises are located in an area undergoing transformation into highly sought-after residential district, which positions the deal to be financially advantageous over time,” said Thomas Feldthus, CEO of Saniona.
Saniona will fund the acquisition of DKK 49 million from existing cash reserves but is also evaluating alternative financing options, such as a potential sale and leaseback arrangement, to optimize capital allocation and maintain strategic agility.
For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona’s partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Attachments
Saniona acquires headquarters to secure long-term stability
Ämnen i artikeln
Tullar
Bostadsmarknaden
Inflation
-992x558.webp&w=3840&q=75)
Tullar
Bostadsmarknaden
Inflation
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-950x950.webp&w=3840&q=75)